

## **Neurotech Appoints Dr Neale Fong to its Board**

**Perth, Australia & Malta** – 3 October 2018 – Neurotech International Limited (ASX: NTI) (**Neurotech** or **the Company**), developer of quality medical solutions improving the lives of children with autism, is pleased to announce the appointment of Dr Neale Fong to the board as a Non-Executive Director.

Dr Fong is a registered medical practitioner with over 35 years' experience in a wide range of leadership roles in the private and public hospital systems, and over 20 years' of experience on corporate boards. His strengths lie in governance, leading large executive teams, implementation of reform and change management, developing strategic directions and leading turnarounds. He has held and continues to hold very senior positions in all health care sectors covering government services, private hospitals, academia, health research, public health, aged care and not for profit organisations.

Dr Fong is currently Chair of the Western Australian Country Health Service Board, Chair of the State Government's Ministerial Council for Suicide Prevention Council, Professor of Healthcare Leadership at Curtin University, Executive Chairman of Bethesda Health Care, and a director of several health companies. He is the managing director of his own consulting company, Australis Health Advisory with a strong track record of engagements with state and commonwealth governments, and private and not for profit health companies. He is also involved in several digital health start-ups based in WA, Singapore and China.

Dr Fong's long and distinguished career in the health and medical sectors has seen him take on the role of national President of the Australasian College of Health Service Management, the peak professional body for health executives and Chair of the International Hospital Federation Global Healthcare Management special interest group.

"We are honoured to have Dr Fong, a person of significant influence across healthcare, medical, business, sport, public service and not-for-profit sectors in Western Australia, on the Neurotech Board," said Neurotech's Chairman, Peter O'Connor. "We have no doubt that Dr Fong will contribute key insights to the Company, drawing from his extensive experience across a myriad of fields. We are pleased to welcome Dr Fong and look forward to his contribution to the Company's future."

-ends-

## **About Neurotech**

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of

becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

http://www.neurotechinternational.com. http://www.mentetech.com.

For more information please contact:

Fleur Hudson

Company Secretary

fhudson@tribis.com.au

Tel: +61 (8) 9424 9360